Ventrix is a clinical-stage company developing a new class of injectable biotherapeutics to treat heart disease and other conditions. Ventrix’s technology is centered around biomaterials that mimic native extracellular matrix (ECM) to guide the body to repair and generate new healthy microenvironment and tissue. ECM, the natural scaffolding and framework in which cells reside, is a network of macromolecules that provides structural and biochemical cues. ECM influences all aspects of cell behavior, including proliferation, differentiation, survival, and function. In a Phase 1 clinical trial, Ventrix demonstrated initial safety and feasibility of a cardiac specific ECM hydrogel in patients with ischemic cardiomyopathy. Ventrix is also pursuing clinical development in a rare pediatric heart disease and in patients undergoing CABG surgery as well as preclinical stage development of intravascularly infusible ECM biotherapeutics.